Chronic Antithrombotic Therapy in Post-Myocardial Infarction Patients

Cardiology Clinics

Volumn 26, Issue 2, 2008, Pages 277-288

  Nagarakanti, Rangadham ^a   Sodhi, Sandeep ^b   Lee, Robert ^c   Ezekowitz, Michael ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; DABIGATRAN; FIBRINOGEN RECEPTOR ANTAGONIST; MELAGATRAN; NONSTEROID ANTIINFLAMMATORY AGENT; SULFINPYRAZONE; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; XIMELAGATRAN;

ANGIOPLASTY; ANTICOAGULANT THERAPY; BLEEDING; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERSENSITIVITY; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION TEST; MONOTHERAPY; PATHOGENESIS; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION;

ANTICOAGULANTS; ASPIRIN; AZETIDINES; BENZYLAMINES; HUMANS; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; THROMBOLYTIC THERAPY; THROMBOSIS; TICLOPIDINE; VITAMIN K; WARFARIN;

EID: 41949096470     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.12.017     Document Type: Review

References (43)

1. Morbidity and mortality: 2002 chart book on cardiovascular, lung, and blood diseases (2002), National Heart, Lung, and Blood Institute, Bethesda (MD)
2. Fuster V., Badimon L., Badimon J.J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326 (1992) 242-250
3. Coller B.S., Scudder L.E., Beer J., et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 614 (1991) 193-213
4. Lefkovits J., Plow E., and Topol E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332 (1995) 1553-1559
5. Sherman C.T., Litvack F., Grundfest W., et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 315 (1986) 913-919
6. Jang I.K., Gold H.K., Ziskind A.A., et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lyse with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 79 (1989) 920-928
7. Golino P., Ashton J.H., Glas-Greenwalt P., et al. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 77 (1988) 678-684
8. Gash A.K., Spann J.F., Sherry S., et al. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 57 (1986) 175-177
9. Gawaz M., Neumann F.J., Ott I., et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93 (1996) 229-237
10. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 330 (1994) 1287-1294
11. Foster C.J., Prosser D.M., Agans J.M., et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107 (2001) 1591-1598
12. Faulds D., and Sorkin E.M. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischemic heart disease. Drugs 48 (1994) 583-598
13. Maalej N., and Folts J.D. Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Circulation 93 (1996) 1201-1205
14. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
15. Lewis H.D., Davis J.W., Archibald D.G., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 309 (1983) 396-403
16. Cairns J.A., Gent M., Singer J., et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 313 (1985) 1369-1375
17. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 336 (1990) 827-830
18. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
19. Mehta S.R., Yusuf S., Peters R.J., et al., Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
20. Takahashi H., Wilkinson G.R., Nutescu E.A., et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance doses of warfarin in Japanese, Caucasians and African Americans. Pharmacogenet Genomics 16 (2006) 101-110
21. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotics and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 204S-233S
22. Wittkowsky A.K., and Devine E.B. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 24 (2004) 1311-1316
23. Fitzmaurice D.A., Blann A.D., and Lip G.Y. Bleeding risks of antithrombotic therapy. BMJ 325 (2002) 828-831
24. Wittkowsky A.K., Whitely K.S., Devine E.B., et al. Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin. Pharmacotherapy 24 (2004) 600-605
25. Mant J., Hobbs F.D.R., Fletcher K., et al., BAFTA investigators. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370 (2007) 493-503
26. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. [abstract]. Lancet 350 (1997) 389-396
27. Anand S.S., Yusuf S., Pogue J., et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results. Circulation 98 (1998) 1064-1070
28. Fiore L.D., Ezekowitz M.D., Brophy M.T., et al. Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 105 (2002) 557-563
29. van Es R.F., Jonker J.J., Verheugt F.W., et al. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial. Lancet 360 (2002) 109-113
30. Jeddy A.S., and Gleason B.L. Aspirin and warfarin versus aspirin monotherapy after myocardial infarction. Ann Pharmacother 37 (2003) 1502-1505
31. Brouwer M.A., van den Bergh P.J., Aengevaeren W.R., et al. Aspirin plus Coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis (APRICOT-2). Trial Circulation 106 (2002) 659-665
32. Hurlen M., Abdelnoor M., Smith P., et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347 (2002) 969-974
33. Harrington R.A., Becker R.C., Ezekowitz M., et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 513S-548S
34. Eriksson U.G., Bredberg U., Hoffmann K.-J., et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 31 (2003) 294-305
35. Johansson L.C., Frison L., Lofgren U., et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 42 (2003) 381-392
36. Sarich T.C., Peters G.R., Wollbratt M., et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran. Clin Pharmacokinet 42 (2003) 485-492
37. Johansson L.C., Andersson M., Fager G., et al. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran, following oral administration of ximelagatran, a novel, oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 42 (2003) 475-484
38. Eriksson-Lepkowska M., Thuresson A., Johansson S., et al. The oral direct thrombin inhibitor ximelagatran has no effect on the pharmacokinetics of P450-metabolized drugs. Pathophysiol Haemost Thromb 32 (2002) 130
39. Eriksson U.G., Bredberg U., Gislén K., et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young, healthy male subjects. Eur J Clin Pharmacol 59 (2003) 35-43
40. Fager G., Eriksson-Lepkowska M., Frison L., et al. Influence of acetylsalicylic acid on the pharmacodynamics and pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor H 376/95. Eur Heart J 21 (2000) 441
41. Wallentin L., Wilcox R.G., Weaver W.D., et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet 362 (2003) 789-797
42. Stangier J., Rathgen K., Stahle H., et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64 3 (2007) 292-303
43. Ezekowitz M.D., Reilly P.A., Nehmizn G., et al. A dose exploration pilot study of dabigatran, a novel oral direct thrombin inhibitor, with and without concomitant acetylsalicylic acid, in comparison to warfarin in patients with non-valvular atrial fibrillation (PETRO Study). Am J Cardiol 100 (2007) 1419-1426